基托桑/聚乙烯醇基磁性水凝微球,具有可控保留和可调节的药物释放,用于静脉灌注
Peinan Yin1, Chengxiong Wei1, Anamaria Brozovic2
1State Key Laboratory of Structural Analysis, Optimization and CAE Software for Industrial Equipment, School of Mechanics and Aerospace Engineering, Dalian University of Technology, Dalian 116024, China.
International journal of biological macromolecules
|December 10, 2024
概括
新的磁性水凝微球通过使药物长期保留和可控释放成为可能,为改善膀癌治疗提供了改善. 这种方法旨在减少在静脉内灌注治疗期间与频繁排尿相关的副作用.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 肠道灌注是一种有效的膀癌治疗方法,但会导致经常排尿.
- 目前的治疗方法缺乏在膀中持续保留药物.
- 开发新的药物输送系统对于改善膀癌治疗至关重要.
研究的目的:
- 开发磁性水凝微球 (DOX-mMSs),用于增强静脉内药物输送.
- 为了在膀中实现多克索鲁比辛 (DOX) 的长期保留和受控释放.
- 在膀癌治疗中减轻频繁排尿的副作用.
主要方法:
- 使用聚乙烯醇 (PVA) /花素 (CS) 制造磁性水凝微球,其中包含磁纳米粒子 (MNP) 和多克索鲁比 (DOX).
- 使用应用磁场 (AMF) 进行磁力启动的DOX-mMS的长期保留.
- 设计基于酸盐解离和酸键的pH敏感药物释放机制.
主要成果:
- 通过DOX-mMS测试,可以证明膀内有高效的磁性保留.
- 微米大小的DOX-mMS允许方便的注射和分泌.
- 敏感的pH特性使得可根据尿液pH值调节的多克索鲁素释放.
- 双重控制策略显示了对静脉内治疗疗效的前景.
结论:
- 磁性水凝微球为膀癌中持续的静脉内药物输送提供了一个有希望的策略.
- 磁性保留和pH触发释放的双重控制增强了治疗潜力.
- 这种方法可以显著改善患者的遵守和膀癌的治疗结果.
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...


